Document is current
Any future updates will be listed below
-
Authors
Cragg, Mark S. https://orcid.org/0000-0003-2077-089X
Yu, Xiaojie
Paluch, Christopher https://orcid.org/0000-0002-9087-1920
Davis, Simon J. https://orcid.org/0000-0002-2280-1170
- License Information
-
More Information
Article History
Accepted: 13 April 2026
First Online: 19 May 2026
Competing interests
: The authors declare the following competing financial interests. M.S.C. is a retained consultant for BioInvent International and has performed educational and advisory roles for Baxalta and Boehringer Ingleheim. He has consulted for GSK, Radiant, iTeos Therapeutics, Surrozen, Hanall, Argenx and Mestag, and received research funding from BioInvent, Surrozen, GSK, UCB and iTeos. C.P. is an employee of MiroBio, a wholly owned subsidiary of Gilead Sciences. S.J.D. was the Founding Director of MiroBio and is now a consultant for Gilead Sciences, and is a named inventor on patents describing agonistic antibodies specific for immune receptors.
